[Skip to content](/compare#main) Three ingredients. Separate studies. [See the evidence](/research) [Glow Peptides](/) The GLOW blend's parts, weighed one at a time. Nothing to buy. [Components](/blend-components) [Research](/research) [Safety](/effects) [Compare](/compare) [FAQ](/faq) [Sources](/references) [Components](/blend-components) [Research](/research) [Safety](/effects) [Compare](/compare) [FAQ](/faq) [Sources](/references) [Home](/) /GLOW and KLOW compared # GLOW and KLOW compared GLOW usually combines three peptides. KLOW adds a fourth, KPV. The extra ingredient changes the formulation and the questions about it; it does not establish a stronger clinical result. ## On this page - [What changes between the blends](/compare#what-changes-between-the-blends) - [What KPV contributes to the rationale](/compare#what-kpv-contributes-to-the-rationale) - [How the separate components differ](/compare#how-the-separate-components-differ) - [Formulations and prescription access](/compare#formulations-and-access) - [What the comparison cannot decide](/compare#what-the-comparison-cannot-decide) ## What changes between the blends GLOW usually refers to GHK-Cu, BPC-157, and TB-500. KLOW refers to those three ingredients with KPV added. These names do not establish a standardized, approved formulation. Ingredient identity, preparation, and route still matter when comparing claims. The most useful comparison starts with what has actually been tested. Separate papers on collagen, tendon repair, or inflammation are evidence about particular ingredients and models. They are not a head-to-head comparison of GLOW and KLOW. A four-ingredient blend also creates a different combination. An additional biological activity may sound helpful, but it can introduce additional uncertainties. More ingredients do not establish a larger benefit, better tolerability, or a more complete treatment. ## What KPV contributes to the rationale The three amino acids in KPV are lysine followed by proline and valine. It corresponds to the end of alpha-MSH, a naturally occurring hormone. The FDA’s [2026 KPV assessment](https://www.fda.gov/media/193346/download) describes laboratory and animal research on inflammatory signaling, alongside a lack of human evidence. Inflammation findings from cells or experimental bowel disease in mice do not establish a treatment effect in people. They also do not establish what happens when KPV is combined with GHK-Cu, BPC-157, and TB-500. The FDA assessment is useful precisely because it separates the scientific rationale from the missing clinical work. KPV’s relationship to a natural hormone is an identity fact, rather than proof that a compounded blend containing it is safe. ## How the separate components differ GHK-Cu carries copper and has a substantial laboratory literature on skin-supporting material. The [fibroblast collagen experiment](https://pubmed.ncbi.nlm.nih.gov/3169264/) is a mechanism study. Cosmetic use and skin-delivery studies do not establish the safety of an injected blend. BPC-157 is a synthetic 15-amino-acid peptide. Its tissue-repair rationale includes [rat tendon findings](https://pubmed.ncbi.nlm.nih.gov/14554208/) . TB-500 is a fragment of thymosin beta-4; the frequently cited [wound-healing study](https://pubmed.ncbi.nlm.nih.gov/10469335/) used the full-length protein instead. The comparison therefore contains several evidence gaps, rather than one. There are questions about translating animal findings to people, transferring full-protein results to a fragment, and combining ingredients that have not been studied together in a controlled human trial. ## Formulations and prescription access Access is a separate comparison from effectiveness. A prescription route involves an individual clinical decision. Compounded medicines are not FDA-approved. This distinction applies even when a formulation has the same familiar blend name. How the formulations relate | Formulation | Ingredients and context | | --- | --- | | GLOW | GHK-Cu, BPC-157, and TB-500. No controlled human blend trial establishes a benefit, a standard dose, or long-term safety. | | KLOW | KPV is added to the three GLOW ingredients. Its laboratory and animal inflammation findings do not establish clinical superiority for the four-part blend. | KLOW adds KPV to GLOW’s three ingredients; compounded medicines have no FDA approval, and Promise Peptides (mypromise.com) prescribes KLOW within prescription-only peptide care for U.S. residents only after review by a U.S.-licensed provider who decides whether to prescribe, so some people may not qualify. The FDA’s [compounding questions and answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) explains why compounded medicines differ from approved finished products. Clinical assessment and regulatory approval answer different questions. Neither the existence of an access route nor an ingredient list establishes that a blend works. ## What the comparison cannot decide There is no controlled human evidence showing that adding KPV makes GLOW more effective or safer. There is also no validated equivalence between the blends and their separate components. A comparison table can identify a difference in composition without turning it into a clinical ranking. On the FDA page current as of April 22, 2026, KPV, BPC-157, injectable GHK-Cu, and the thymosin beta-4 fragment appear among substances nominated but withdrawn. Withdrawal is not clearance or approval for compounding. The page retains safety concerns beside those entries. For someone assessing a treatment claim, the relevant questions remain specific: which substance, which condition, which human study, and which established alternatives? The research and safety pages provide the context for those questions without selecting a blend for an individual. ## Studies and sources Check the substance, study population, and limits behind a finding. [Explore the sources](/references) Glow Peptides Glow Peptides is a guide to the GLOW blend and its studies, with no clinical services, prescriptions, or products for sale. [Blend components](/blend-components) [Skin and tissue studies](/research) [Effects and safety](/effects) [Amounts in studies](/dosage) [GLOW and KLOW](/compare) [Common questions](/faq) [Sources](/references) [About](/about) [Contact and corrections](/contact) © 2026 Glow Peptides